Oncology Corporate Profile
Apricus Bio is a San Diego-based specialty pharmaceutical company, with commercial products and a broad pipeline across numerous therapeutic classes. Revenues and growth are driven from the sales of the Company's commercial products through its Apricus Pharmaceuticals USA, Inc. and NexMed (USA), Inc. subsidiaries and through out-licensing in certain territories of its product pipeline and NexACT® technology. Apricus Bio currently markets Totect® (dexrazoxane HCl), the only drug approved in the US for the treatment of anthracycline extravasation. Apricus Bio's current pipeline includes Vitaros®, approved in Canada for the treatment of erectile dysfunction, as well as compounds in development from pre-clinical through pre-registration currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Consumer Healthcare.
|Granisol®||granisetron||Granisol® is indicated for the prevention of: Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation.|
|Totect®||dexrazoxane HCl||Totect® is indicated for the treatment of extravasation resulting from intravenous anthracycline chemotherapy.|
View additional information on commercial products here »
This company does not have any pipeline products
3/27/2017 07:04 pm
3/20/2017 01:00 pm
3/17/2017 05:00 pm
3/13/2017 09:02 pm
3/13/2017 09:02 pm
3/13/2017 08:03 pm
3/13/2017 08:02 pm
[GlobeNewswire] - Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals Strengthens Financial Position Vitaros U.S. NDA Re-Submission on Track for Third Quarter 2017 Conference Call / Webcast Today, Monday, ...